Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Unda

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Actas Urologicas Espanolas|October 21, 2022
Hormone sensitive protocol for metastatic prostate cancer, an updateJ L Álvarez Ossorio, M Rodrigo Aliaga, A Rodríguez Antolin, et al.
Actas Urologicas Espanolas|March 14, 2017
Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study - GESCAP groupF Gómez-Veiga, A Rodríguez-Antolín, B Miñana, et al.
Actas Urologicas Espanolas|March 20, 2022
Non-metastatic castration-resistant prostate cancer: management recommendationsA Alcaraz Asensio, J L Alvarez Ossorio, J M Cozar Olmo, et al.
Actas Urologicas Espanolas|January 4, 2018
Safety and efficacy of various strains of bacille Calmette-Guérin in the treatment of bladder tumours in standard clinical practiceM Unda-Urzaiz, J M Cozar-Olmos, B Miñana-Lopez, et al.
Actas Urologicas Espanolas|July 1, 1997
[Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections]J M Martínez Jabaloyas, S Sanz Chinesta, J F Jiménez Cruz, et al.
Actas Urologicas Espanolas|May 28, 2013
Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): positioning statement from the Spanish Association of UrologyH Villavicencio, C Hernández, A Gómez, et al.
British Journal of Cancer|June 27, 2013
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO studyA Alcaraz, R González-López, J Morote, et al.
The Journal of Urology|September 3, 2013
Bladder cancer in Spain 2011: population based studyB Miñana, J M Cózar, J Palou, et al.
British Journal of Cancer|June 1, 2013
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO studyC de la Piedra, A Alcaraz, J Bellmunt, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Actas Urologicas Espanolas|October 21, 2022
Hormone sensitive protocol for metastatic prostate cancer, an updateJ L Álvarez Ossorio, M Rodrigo Aliaga, A Rodríguez Antolin, et al.
Actas Urologicas Espanolas|March 14, 2017
Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study - GESCAP groupF Gómez-Veiga, A Rodríguez-Antolín, B Miñana, et al.
Actas Urologicas Espanolas|March 20, 2022
Non-metastatic castration-resistant prostate cancer: management recommendationsA Alcaraz Asensio, J L Alvarez Ossorio, J M Cozar Olmo, et al.
Actas Urologicas Espanolas|January 4, 2018
Safety and efficacy of various strains of bacille Calmette-Guérin in the treatment of bladder tumours in standard clinical practiceM Unda-Urzaiz, J M Cozar-Olmos, B Miñana-Lopez, et al.
Actas Urologicas Espanolas|July 1, 1997
[Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections]J M Martínez Jabaloyas, S Sanz Chinesta, J F Jiménez Cruz, et al.
Actas Urologicas Espanolas|May 28, 2013
Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): positioning statement from the Spanish Association of UrologyH Villavicencio, C Hernández, A Gómez, et al.
British Journal of Cancer|June 27, 2013
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO studyA Alcaraz, R González-López, J Morote, et al.
The Journal of Urology|September 3, 2013
Bladder cancer in Spain 2011: population based studyB Miñana, J M Cózar, J Palou, et al.
British Journal of Cancer|June 1, 2013
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO studyC de la Piedra, A Alcaraz, J Bellmunt, et al.
Pageof 8